Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients

Nephrology

Volumn 12, Issue 6, 2007, Pages 539-545

  Takahashi, Nobunori ^a   Kojima, Toshihisa ^a   Ogawa, Hiroshi ^b   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinseikai Dai Ichi Hospital   (Japan)

Author keywords

Correlation; Diabetes mellitus; Diabetic nephropathy; Haemodialysis; Renal osteodystrophy; Specific bone metabolism marker

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; GLUCOSE; PARATHYROID HORMONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

AGED; ALKALINE PHOSPHATASE; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 35848944669     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00829.x     Document Type: Article

References (27)

1. Inaba M, Okuno S, Nagasue K et al. Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am. J. Kidney Dis. 2001 38 : S139 42.
2. Pei Y, Hercz G, Greenwood C et al. Renal osteodystrophy in diabetic patients. Kidney Int. 1993 44 : 159 64.
3. Aubia J, Bosch J, Lloveras J et al. Low incidence of hyperparathyroidism in diabetic renal failure. Proc. Eur. Dial. Transplant Assoc. Eur. Ren. Assoc. 1985 21 : 902 8.
4. Levy JR, Murray E, Manolagas S, Olefsky JM. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 1986 119 : 1786 92.
5. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol. Dial. Transplant. 1998 13 : 2294 302.
6. Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur. J. Med. Res. 1998 3 : 81 8.
7. Ueda M, Inaba M, Okuno S et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am. J. Kidney Dis. 2002 4 : 802 9.
8. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J. Am. Soc. Nephrol. 1996 7 : 506 12.
9. Alvarez L, Torregrosa JV, Peris P et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J. Bone Miner Metab. 2004 22 : 254 9.
10. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997 43 : 2058 63.
11. Montagnani A, Gonnelli S, Cepollaro C et al. A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur. J. Intern. Med. 2003 14 : 172 7.
12. 3 in patients with type 2 diabetes. Osteoporos. Int. 1999 9 : 525 31.
13. Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: Role of phosphorus, calcium, and gender. J. Clin. Endocrinol. Metab. 1998 83 : 3860 66.
14. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol. Dial Transplant. 2002 17 (Suppl 2 21 4.
15. WHO Expert Committee. Second Report on Diabetes Mellitus. Technical report series 646. Geneva : WHO, 2003 180 89.
16. McSheehy PM, Chambers TJ. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986 118 : 824 8.
17. Athanasou NA. Current concepts review - Cellular biology of bone-resorbing cells J. Bone Joint Surg. Am. 1996 78 : 1096 112.
18. Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki C. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol. Dial. Transplant. 1994 9 : 1751 8.
19. Inaba M, Nishizawa Y, Shioi A, Morii H. Importance of sustained high glucose condition in the development of diabetic osteopenia: Possible involvement of the polyol pathway. Osteoporos. Int 1997 7 (Suppl 1 S209 12.
20. Kanatani M, Sugimoto T, Kano J, Kanazawa M, Chihara K. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J. Cell Physiol. 2003 196 : 180 89.
21. Ueda M, Inaba M, Okuno S et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci. 2005 77 : 1130 39.
22. Coen G, Ballanti P, Baducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol. Dial. Transplant. 2002 17 : 233 8.
23. Endres DB, Villanueva R, Sharp CF et al. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: Performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin. Chem. 1991 37 : 162 8.
24. Yumita S, Suzuki M, Akiba T et al. Levels of serum 1,25 (OH) 2D in patients with pre-dialysis chronic renal failure. Tohoku J. Exp. Med. 1996 180 : 45 56.
25. Mori S, Harada S, Okazaki R et al. Hypomagnesemia with increased metabolism of parathyroid hormone and reduced responsiveness to calcitropic hormones. Intern. Med. 1992 31 : 820 24.
26. Stock JL, Coderre JA, Posillico JT. Effects of estrogen on mineral metabolism in postmenopausal women as evaluated by multiple assays measuring parathyrin bioactivity. Clin. Chem. 1989 35 : 18 22.
27. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am. J. Kidney Dis. 2003 41 : 523 31.